46
Participants
Start Date
September 16, 2020
Primary Completion Date
December 14, 2022
Study Completion Date
August 15, 2024
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
NYU Langone Health, New York
NYU Langone Health
OTHER